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Shifting Collaborations and the Quest for Legitimacy: Observation of Regenerative Medicine 
Research in Japan 
 
Koichi Mikami 
Science, Technology and Innovation Studies, 
University of Edinburgh 
 
Introduction 
 
On 12 June 2012, the Japanese Society for Regenerative Medicine (JSRM) held a public lecture in 
Yokohama, a harbour city about 30 kilometres south of Tokyo, as part of its 11th Annual Congress. 
The congress was one of the biggest events in the field of regenerative medicine research in several 
years, not just because it was a once-a-year opportunity for Japanese researchers in this growing 
field to gather and present their latest achievements but also because it was held consecutively with 
the annual meeting of the International Society for Stem Cell Research (ISSCR), the international 
academic society of stem cell scientists. Approximately 800 people attended this two-hour lecture 
(11th Congress of JSMR, 2012), and I was one of them. In the conference room where the lecture 
took place, I saw a large number of patients, some of whom were in wheelchairs, their families and 
caretakers, the recognisable faces of some researchers surrounded by the flocks of businesspeople 
and many individuals whom I did not recognise and whom possibly the category of ‘public’ applies 
to. 
 
The programme of the lecture listed three academic speakers along with a non-academic 
commentator. Yoshiki Sawa, the chair of this event and also that of the JSRM annual congress, 
invited the first speaker Shinya Yamanaka, a stem cell scientist known for his reprogramming 
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technique to create induced pluripotent stem (iPS) cells.1 Yamanaka opened his talk with casual 
conversation with the chair and the non-academic commentator Takuro Tatsumi – a Japanese actor 
later revealed to be a senior alumnus of the high school that Yamanaka himself attended – and then 
explained his future visions of iPS cell research. As soon as he finished his talk he had to leave the 
room, and the lecture moved on to the second speaker Teruo Okano, a biomedical engineer who 
developed a technique called ‘cell sheet engineering’2 and who is also the president of the JSRM. In 
his presentation, he demonstrated various achievements of his research group and presented his 
vision of making ‘organ factory’, which is a manufacturing approach to produce artificial tissues and 
organs for transplantation therapy. The final speaker was Sawa himself, who is a cardiovascular 
surgeon renowned for his experiences in heart transplantation. In his talk, three other individuals not 
listed on the programme approached the stage: they were Sawa’s former patients who received 
‘myoblast cell sheet therapy’ 3 for heart disease, invited as panel speakers to comment on their 
experiences and explain how the therapy improved the quality of their life. 
 
Each of these speakers at this JSRM public lecture, including Sawa’s former patients, is appropriate 
for the main theme of regenerative medicine research in Japan and, given that Yamanaka became 
the president of the ISSCR after its Yokohama meeting, the selection of the speakers indicated the 
chair’s intention to present ‘the state of art’ in this research field to the curious public. Yet, this 
lecture simultaneously embodied ‘the state of collaboration’ in this field, as each academic speaker 
has a different disciplinary background, representing a different stance in regenerative medicine 
research, and, from a social scientist’s perspective, the question of why they were all there to speak 
                                                 
1  Yamanaka invented a technique to induce the similar biological properties to embryonic stem cells to already-
differentiated cells of an adult body, creating iPS cells, and for this invention he received the Nobel Prize in 2012. 
2 Cell sheet engineering is an bio-engineering technique to culture cells in a special petri dish with temperature-responsive 
polymer coating, which allows researchers to collect cells in a form of a sheet, making it easy to use for both research and 
therapeutic purposes. 
3 Myoblast cell sheet therapy is a clinical application of the abovementioned cell sheet engineering, and myoblast cells 
obtained from the patient’s thigh were cultured as a cell sheet, which was applied to the patient’s heart to strengthen its 
function. 
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is worthy of a sociological investigation. Furthermore, the specific audience whom each of them 
tried to engage also seems reflective of the structure of this research field. 
 
While collaboration in research can be studied at various levels (see Katz and Martin, 1997), in this 
chapter I examine collaborations in the field of regenerative medicine research in Japan as the 
configurations of ‘clusters’, or formal and informal social ties and groupings of different actors. The 
field of regenerative medicine research is not only interdisciplinary but also argued to lack an 
agreed-upon definition (Morrison, 2012), and by examining how the clusters have evolved in Japan 
since 2000, I aim to assess the symbolic significance of the 2012 JSRM lecture for this emerging 
field. The collaborations in the field are not necessarily directed towards the publication of a 
scientific article but more likely towards the invention of medical technology, and such 
collaborations are difficult to assess using bibliometric approaches, as no ‘list’ of collaborators 
would be produced in the attainment of this goal (Katz and Martin, 1997). Thus, in my analysis, I 
draw on the qualitative data collected during five years of sociological fieldwork, including in-depth 
interviews, reviews of scientific articles and policy documents, and observations at meetings and 
conferences, all conducted from late 2007 through early 2012. 
 
Throughout the chapter, I employ the term ‘cluster’ to describe social ties and groupings observed in 
this field for several reasons. Firstly, despite the academic speakers’ distinctive disciplinary 
backgrounds, the term ‘cluster’ is more fitting than ‘discipline’ because disciplines are the 
categories emerged as ‘the result of specialization in scientific practice, in terms of the scientific 
questions pursued and the hypothesis addressed’ (Penders et al., 2008: 748). The speakers under this 
study share practices and visions not only with their fellow scientists but also with many other 
actors, including funding bodies, corporate partners and even patients and their families. Moreover, 
the boundaries of clusters are neither self-evident nor fixed, and for this reason even those clustered 
themselves may not be conscious of their belonging to one or other. As indicated above, the clusters 
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in this field have evolved over the last decade or so, and as such different constituents now than 
several years ago without them necessarily changing their practices. It is also important to 
emphasise that while the boundaries of clusters are not evident at the first blush, they are certainly 
there, and reflecting this point I find the term ‘cluster’ more appropriate than ‘network’, which often 
refers to a linkage of different actors. To refer to what creates the sense of belonging to each cluster, 
I deploy the word ‘style’, following Fujimura and Chou’s phrase of ‘styles of practice’, defined as 
‘historically located and collectively produced work processes, methods and rules for constructing 
data and theories and verifying theories’ (1994: 1017; also cited in Penders et al., 2008). Yet again, I 
do not limit the use of this term to that of ‘scientific’ practices and instead apply it to a spectrum of 
practices and visions involved in regenerative medicine research. 
 
The following sections are ordered nearly chronologically. This study starts in the year 2000, when 
regenerative medicine research became part of a large-scale, national project in this country. As a 
result of this turn-of-the-millennium policy initiative, Japanese regenerative medicine research came 
to resemble ‘big science’ observed in the latter half of the twentieth century, characterised not only 
by its volume of funding invested and its number of scientists committed but also by its alignment 
with non-scientific goals, be it political, economic, or military, and the effort to coordinate different 
sets of expertise to attain them (e.g. Kelves, 1995; Galison, 1992; Galison and Hevly, 1992). Thus, 
the year 2000 serves as a reasonable starting point for addressing complex interactions of various 
actors in this field. As previous studies on research collaboration suggest, becoming ‘big science’ is 
not always positive and may come with some costs (e.g. Katz and Martin, 1997; Vermeulen et al., 
2010; Weinberg, 1961). Such costs are not only financial, related to the effort of coordinating the 
collaboration, but also social, associated with the tension arisen within it. While perhaps desirable 
for maintaining diversity in the field and granting some autonomy to scientists (Vermeulen et al., 
2010), the conventional style of small laboratory-based life science research poses significant 
hurdles for regenerative medicine research in Japan to be coordinated as ‘goal-sharing’ big science. 
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Therefore, the actors under this study have actively (re-)configured their collaborations so as to 
achieve legitimacy in this field. 
 
The quest for legitimacy has been a complex process not only because the research field is 
interdisciplinary but also because of the commitment of the government in the early 2000s rejecting 
the style of ‘pure’ science, in which one’s scientific legitimacy is achieved by conducting good 
research and gaining credibility in the scientific community, and instead demanding the shift toward 
‘clinically relevant’ research (cf., Albert and Kleinman, 2011; Bourdieu, 1999; Latour and Woolgar, 
1979; Maienschein, 1993). Yet, the cluster of stem cell scientists had difficulties with adjusting their 
rules and hence changing their styles; biomedical engineers and surgeons, in contrast, came together 
as another cluster, appreciating the value of patient participation, though it was only possible under a 
specific legal condition. This situation changed dramatically in 2007 when Yamanaka created 
human iPS cells, and this event offered a new interpretation of ‘clinical relevance’. Having been less 
successful in its commitment with stem cell science, the government was keen to seize this 
emerging opportunity and introduced new rules in this field, which again provoked unexpected 
responses from different research clusters. This Japanese case therefore presents the struggle of 
shaping a scientific field with the commitment of non-scientific actors, the government in particular. 
If ‘big science’ is to be understood as the coordination of research for non-scientific goals (Galison, 
1992), then life science research will likely have more of it; yet, as this case shows, there can be a 
counter move to retain its smallness and hence its purity. 
 
From Stem Cell Science to Regenerative Medicine Research 
 
The new millennium was an important turning point for Japanese science and technology policy. 
The nation experienced the burst of economic bubble in early 1990s, and little recovery in its 
economy was observed in its ensuing years (cf., Hayashi and Prescott, 2002). Japan has few natural 
resources to capitalise on, and hence the government viewed advances in science and technology as 
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promising sources for the nation’s recovery, just as they were for the nation’s dramatic economic 
growth in 1970s and 1980s. To promote science and technology within the country, the government 
enacted the Science and Technology Basic Law and then established the Council of Science and 
Technology Policy as its internal advisory body in 1995. The Law (1995) stipulates that, upon its 
consultation with the Council, the government must publish Science and Technology Basic Plans 
(STBPs) every five years, explicating national strategies for promoting science and technology and 
also for coordinating plans of related ministries. The first STBP was published in 1996, but this 
document simply pointed out the need for building national research capacities, suggesting that the 
size of research population needed to increase and that better research infrastructure ought to be 
developed (STBP, 1996). It required several more years before the government strategically 
committed to promoting certain areas of science, and both the Millennium Projects launched in 2000 
and the second STBP published in 2001 marked this policy shift. 
 
The Millennium Projects were large-scale government research initiatives focusing on three key 
themes in modern society – information, ageing and environment. By addressing these themes, 
research projects were expected to ‘resolve the problems that human race would face’ and ‘result in 
technological innovation developing new industries’ (Kantei, 1999). The government called for 
research proposals in 1999, and the selected projects commenced in April 2000. As part of the 
Millennium Genome Project, stem cell science was conducted over five years, corresponding to the 
theme of ageing. A significant milestone in this national project was the establishment of RIKEN 
Center for Developmental Biology (CDB) in the harbour city of Kobe in 2000, which has been a key 
figure in Japanese regenerative medicine research since then. The second STBP (2001) endorsed the 
visions underlining the Millennium Projects and listed information technology, environmental 
sciences and life sciences as the national priorities along with five other items. In the section of life 
sciences, the government clearly stated that it would focus on ‘cellular biology, so as to achieve 
advances in organ transplantation and regenerative medicine’ (STBP, 2001: 22–3). Thus, this 
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document officially listed regenerative medicine as an important target for Japan’s science and 
technology. 
 
Enjoying substantial political support for the Millennium Genome Project, Japanese stem cell 
science made significant progress over the five years of period but its progress was not fully aligned 
with the original intent of the government. As suggested in the second STBP, the government 
expected stem cell science to produce ‘clinically useful’ knowledge, but many research 
achievements were in animal-based studies on cellular development, differentiation and 
regeneration. The interim assessment report of the Millennium Genome Project published in 2003 
highlighted the need for clear plans to make a transition from basic science to applied research 
(Kantei, 2003). Like other areas of basic biology, animal cells have been widely used to study 
biological mechanisms of cellular development, differentiation and regeneration, but, in contrast, 
human cells, which are critical to understand clinical implications of such mechanisms, were 
difficult to obtain and only a handful of researchers at university hospitals had access to the cells of 
donor patients. Despite the significance of RIKEN CDB’s location adjunct to a research-focused 
hospital, stem cell scientists had difficulties with collaborating with medical doctors, who tend to be 
more interested in improving therapeutic approaches (cf., Cambrosio et al., 2006). The final 
assessment report published in 2006 stated that the outcomes of stem cell science were ‘not ready 
for clinical applications’, leading to the conclusion that the next step was to consider the move into 
‘translational research’ (Kantei, 2006). 
 
Stem cell scientists were not entirely responsible for this mismatch, and the case of human 
embryonic stem (hES) cell research demonstrates how policy decisions also contributed to it. The 
growing expectation for stem cell science to make medical innovation at the beginning of the new 
millennium was partly the result of the establishment of the first hES cell lines by the American 
scientist James Thomson in 1998. This special type of stem cells has two significant abilities, an 
ability to be any kind of cells constituting human body and the other to proliferate unlimitedly. 
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These abilities would potentially offer significant advantages for their therapeutic use. However, 
how nations reacted to these stem cells varied considerably due to the ethical concerns about their 
research use (Gottweis et al., 2009). The US government announced in 2001 that the National 
Institutes of Health would only support hES cell research using already established cell lines, and in 
contrast the UK government authorised research on hES cells for the purpose of developing new 
treatments under its Human Fertilisation and Embryology (Research Purposes) Regulation 2001. In 
the same year, the Japanese Ministry of Education, Culture, Sports, Science and Technology 
(MEXT) also manifested its attitude toward these cells in its Guidelines for Derivation and 
Utilization of Human Embryonic Stem Cells. 
 
The Guidelines (2001) did not ban hES cell research but rather made it difficult to undertake it in 
Japan particularly for two reasons. Firstly, the Guidelines stated that ‘a human embryo is a 
beginning of life’ and that ‘human ES cells have the potential to differentiate into any types of 
human cells’ (2001: Article 3). Following this idea, the Guidelines required both derivation and use 
of hES cells to pass a dual review process: firstly by the institutional review board of one’s 
organisation and then by the Ministry, thereby rendering hES cell research both labour-intensive and 
time-consuming. Secondly, the Guidelines undermined the ‘therapeutic promise’ of hES cells – 
limiting the need for hES cell research in Japan and rejecting the powerful argument for making hES 
cell available for research in some other countries (cf., Rubin, 2008). By stating that ‘clinical 
research applying human ES cells or cells originated from them to the human body, and utilization 
of them in medicine and in its related fields’ ought not to be carried out ‘until specific criteria other 
than the Guidelines have been established’ (2001: Article 2.2), they caused great uncertainty over 
medical significance of these cells. This policy decision discouraged the researchers to conduct hES 
cell research. As a result, Japanese stem cell science progressed without much action in hES cell 
research (Nakatsuji, 2007), and many researchers chose to study mouse ES cells for their basic 
research, which exhibit fewer ethical concerns and have been available for long time. Thus, the 
Guidelines enlarged the gap between basic and applied research in stem cell science. 
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In accordance with the original STBP policy vision of promoting the production of clinically useful 
knowledge, MEXT decided to push other areas of stem cell science towards a more clinical 
orientation, rather than overturning its decision on hES cell research, and launched the ‘Project for 
Realization of Regenerative Medicine’ in 2003. As its title shows, this project was designed to focus 
on clinical applications of stem cells, and the two of its three principal investigators were based at 
university hospitals, encouraging the kind of collaboration that the Millennium Genome Project was 
not successful to initiate. Yet, the project leader and the third principal figure were nominated from 
RIKEN CDB and hence the project was complementary to stem cell science in the Millennium 
Genome Project, which ended in 2005. Among various non-hES cells, mesenchymal and 
haematopoietic stem cells in particular were considered to be promising sources for regenerative 
medicine in this project, and this led to the establishment of a cord blood stem cell bank. This bank 
was expected to provide stem cell scientists with easy access to ethically-sourced human multipotent 
stem cells, just as the UK Stem Cell Bank was designed for hES cells (Stephens et al., 2008). This 
project ran its first term for five years, and it was in its fifth and final year when Yanamaka’s 
research group announced its creation of human iPS cells – an innovation that dramatically changed 
the state of Japanese regenerative medicine research. 
 
Collaborations at University Hospitals 
 
While MEXT struggled to let stem cell scientists work on human cells, several other actors were 
actively working on them already, and the works of Teruo Okano and Yoshiki Sawa illuminates this 
side of the field. Okano developed the abovementioned ‘cell sheet engineering’ technique in the 
mid-1990s. When cells are cultured in a petri dish, usually an enzyme needs to be applied to isolate 
them for collection but its application also causes some damage to the cells. To resolve this problem, 
Okano invented a special petri dish with temperature-responsive polymer coating: this invention 
allows the cultured cells to be collected in the form of a sheet simply by changing its temperature 
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without causing any damage (Okano et al., 1995). The cell sheet removed from the petri dish can 
also be applied directly onto the site of the body in need of therapy, rather than releasing the cells 
into the body by injection. This new approach is expected to be more effective for therapy because 
most cells stay at the intended site and perform their functions, while the injection approach must 
depend on body’s biological mechanisms to guide the cells to the deformed site. 
 
Okano not only developed this technique but also promoted its clinical applications actively. In 
2001, he established a spin-off company to make his petri dish available for research use. Based at a 
medial university, his research group also teamed up with surgeons and initiated clinical research 
using the technique. Once he began such research, some medical doctors from other university 
hospitals became interested in collaborating with his group. The early successes of such 
collaborations were on cornea and heart therapies. Severe corneal diseases can be treated by 
transplantation and this is a well-established medical practice, but the scarcity of corneal tissues for 
transplantation has been a major challenge. Okano’s technique allows a doctor to culture the cells 
obtained from a patient’s mouth in the form of a sheet, which can be transplanted back to the 
patient’s cornea, rather than depending on cornea donation. Similarly, cells procured from a 
patient’s thigh can be used to produce cell sheets, which are then applied to the heart to treat heart 
failure. This is an attractive alternative to heart transplantation in Japan, where cadaver donors are 
scarce for its socio-historical reasons (cf., Lock, 2002). Yoshiki Sawa was one of Okano’s main 
collaborators for this myoblast cell sheet therapy, and in fact the patients spoke in the 2012 JSRM 
public lecture were the first recipients of this therapy as part of the clinical research jointly 
conducted by Okano and Sawa. 
 
These clinical studies of cell sheet therapies represent a different research cluster of regenerative 
medicine in Japan from that of stem cell science. They focused on adult somatic cells, which are 
already differentiated into certain lineages of cellular development, and mainly dealt with their 
structural matrices, rather than the mechanisms of cell expansion and differentiation. The style of 
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their practice was goal-oriented, which is stereotypic of engineering and medical sciences. This is 
not to suggest that all collaborators in this cluster shared a single goal. Instead, each of these actors 
had a personal goal and in order to attain it, collaboration was critical: while Okano, the biomedical 
engineer, had the special petri dish, he needed access to both the patients and their cells to prove the 
value of his invention as a tool for regenerative medicine. In contrast, Sawa, the surgeon, needed the 
petri dish and the skills in culturing cells to treat his seriously-ill patients, as donated organs were 
unlikely to be available for transplantation. Moreover, because this yet-to-be-approved therapy must 
be conducted as clinical research, the patients needed the surgeon and his authority in medicine to 
take part in it. 
 
In this collaboration, each of the actors also had something to offer to the others. The biomedical 
engineer offered his petri dish, the patients their cells. While these two items are material 
components of this regenerative medicine approach, the space within a hospital, which only the 
surgeon could provide, was indispensable for making their collaboration. Until 2006, no guidelines 
on clinical research using human cells, other than international ethical guidelines, existed and just 
like any other medical practices the research was regulated under the Medical Practitioners Law, 
which is the legal basis of the medical licensing system in Japan. Under this law, the doctors reserve 
the discretionary right to decide how their patients ought to be treated, and are allowed to use drugs 
and devices not yet approved by the government. The condition for conducting clinical studies of 
regenerative medicine was only that both the patient and their cells had to remain under a doctor’s 
control throughout the procedure. For this reason, the cells had to be cultured at a hospital. In other 
words, the collaboration for cell sheet therapy could not have taken place if the surgeon had been 
unable to offer the space for culturing the cells. 
 
Hospital-based collaborations like this produced some clinically promising results but advances in 
clinical applications of adult stem cells have seldom led to commercial applications. As Okano’s 
spin-off company represents, commercial actors existed already in the early 2000s and many of 
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them contributed to such collaborations in one way or another. However, for them, initiating the 
similar research procedure would have been a different issue. In clinical trials, for instance, 
companies must follow the Pharmaceutical Affairs Law, regulating manufacturing of drugs and 
devices, as well as the instructions of the Ministry of Health and Welfare (MHW)4 on cellular 
products. The instructions (MHW, 1999) stipulate that a company must demonstrate both safety and 
efficacy of its product to start the phase-I clinical trial. However, as some company-based 
researchers complain, this requirement is not easy to meet. Firstly, efficacy may not be evident, even 
for the company, as pre-clinical studies only demonstrate the results from animal models and their 
relevance to human subjects is uncertain. Secondly, without clear criteria for product safety, the 
company is expected to be accountable for its product beyond its production line. Unlike in clinical 
research, a product must be delivered to a hospital, and the company has to demonstrate that its 
cellular product remains stable and safe even for this extra period of time. Furthermore, the 
company has to conduct the entire procedure in a strictly controlled working environment, which 
was not a condition necessary for clinical research at hospitals. 5  Therefore, despite their 
participation in the research cluster, many companies were not able to take advantage of it. 
 
The Birth of Induced Pluripotent Stem Cells 
 
Until 2006, the two clusters co-existed with little interactions in Japanese regenerative medicine 
research. One was the cluster of stem cell scientists, emphasising the biological mechanisms of 
cellular development, differentiation and regeneration, progressed with the government support 
since the beginning of the new millennium; and the other was that of biomedical engineers and 
medical doctors, who focused on the therapeutic use of adult somatic cells, with some success on 
                                                 
4 The MHW was re-structured as the Ministry of Health, Labour and Welfare (MHLW) in the 2001 Central Government 
Reform. 
5 This policy gap between academic clinical research and industrial clinical trials existed until 2006, when the MHLW 
introduced its Guidelines on Clinical Research using Human Stem Cells, setting the similar standards for clinical research 
in hospitals (Guidelines, 2006; and also Matsuyama, 2008). 
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treating patients but not on delivering products to the market. However, neither of these clusters was 
able to present its legitimacy in this emerging field and to represent regenerative medicine research: 
the former cluster failed to produce clinically useful knowledge that the government demanded, and 
the latter only operated in a small scale under the privileged status of licensed doctors. The distance 
between the two clusters appeared as though the conventional division of ‘basic’ and ‘applied’ 
research was at work and was large as ever. However, the situation started to change in late 2006 
when Shinya Yamanaka’s research group invented a novel technique to reprogram the biological 
characters of adult cells and created what they called iPS cells from mouse skin cells. 
 
Yamanaka and his colleague Kazutoshi Takahashi (2006) argued that their technique had the 
potential to resolve ethical issues of hES cell research because their cells exhibited the identical 
biological properties as ES cells, but there was a question about its applicability to human cells at 
that time. If only applicable to non-human animals, this technique would not differ much from 
previous cloning techniques and would fail to confirm its clinical relevance – from the government’s 
perspective, this could have been merely another achievement in pure science. In 2007, however, 
Yamanaka succeeded in applying this technique to human skin cells and successfully demonstrated 
its potential clinical relevance (Takahashi et al., 2007). Within a couple of days of this 
announcement, MEXT sent its officers to Yamanaka to evaluate the implications of the technique 
and discuss how the Ministry could support his research further (Hishiyama, 2010). As Thomson’s 
group in the US also reported its success in creating human iPS cells almost at the same time (Yu et 
al., 2007), MEXT sensed the intensity of international competition in this field and took 
responsibility for supporting his research, simultaneously allowing itself to claim credit for its future 
advancement. 
 
Within the couple of months since Yamanaka’s announcement, the government held several 
meetings and he was invited to explain how useful iPS cells would be for regenerative medicine and 
drug development. In these meetings, he suggested that forming a collaborative research network 
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would be indispensable if Japan were to compete against research universities in the US and 
elsewhere (Hishiyama, 2010). MEXT adopted this vision and established the ‘All-Japan’ research 
network for iPS cell research. Central to this network were the Center for iPS Cell Research and 
Application (CiRA), a research institute founded at Kyoto University for and directed by Yamanaka, 
and MEXT’s Project for Realization of Regenerative Medicine. The Project started its second term 
in April 2008, and Yamanaka joined the three principal figures by becoming its fourth core 
researcher. With these developments, the focus of this project also shifted from multipotent stem 
cells to iPS cells, and Shinichi Kousaka, a senior medical scientist was appointed the new project 
leader. Yamanaka also became the director of two other research programmes focusing on iPS cells, 
one with the support of MEXT and the other with that of the Cabinet Office. Here, the collaborative 
network of iPS cell research was established under the government’s initiative. While the members 
belong to different universities and research centres, they were expected to share their latest findings 
and research resources within this network and maintain Japan’s leading position in this emerging 
field. 
 
In addition to the political support, Yamanaka also enjoyed great public support. The news about his 
creation of human iPS cells circulated widely in the Japanese mass media – that a young Japanese 
scientist invented a new technique, resolving one of the significant challenges in cutting-edge life 
science, immediately brought massive popularity (cf., Shineha et al., 2010). Compliments from 
well-recognised political and religious leaders, like the US President and the Pope, also helped this 
phenomenon. The concept that iPS cells could allow one’s cells to be utilised for treating one’s own 
disease, thereby alleviating the problem of organ shortage, was another reason for its popularity in 
this country. To maintain and potentially increase this public support, MEXT has frequently held 
public events around its programmes of regenerative medicine research since the end of 2007, and 
all have been very well attended. The scene of audiences taking photos of Yamanaka has been 
common in such events, indicating Yamanaka’s ‘heroic’ status, representing not only Japanese 
regenerative medicine research but also the community of science. His popularity among the public 
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served to re-vitalise the cluster of stem cell scientists and MEXT promised them another five years 
of its support, despite their persistent struggle to produce clinically useful knowledge. 
 
During this remarkable period for the cluster of stem cell scientists, hospital-based collaborations 
also made some progress. Only several weeks after Yamanaka’s announcement of creating human 
iPS cells, Sawa announced that his first myoblast-therapy patient had made a fast recovery and was 
de-hospitalised. Almost simultaneously, a start-up company Japan Tissue Engineering Co. Ltd. (J-
TEC) completed the series of clinical trials and obtained manufacturing authorisation for its cellular-
based product for the first time in Japan. Among commercial actors, this latter event was considered 
particularly as an important milestone for regenerative medicine in this country, as it demonstrated 
that culturing cells for therapeutic use was no longer confined to a laboratory space within hospitals. 
The scale of the political support as well as the growing public support to iPS cell research, 
however, did not prove advantageous to this cluster. Despite the progress made both at a hospital 
and in the industry, the impact of Yamanaka’s success was so significant that the term ‘iPS cell 
research’ became used synonymously with regenerative medicine research in this country. This by 
no means suggests that Okano’s research group did not receive any government support for its 
research – Okano also obtained a large grant for his cell sheet engineering to realise his vision of an 
‘organ factory’ (CAO, 2009) – yet, neither Sawa nor Okano enjoyed the public support comparable 
to that of Yamanaka and iPS cell research. 
 
In 2009, MEXT, being responsible for advancing iPS cell research and accountable for a substantial 
portion of its financial spending, published a roadmap illustrating the future trajectory of iPS cell 
research over then ensuing 10 years (2009). This trajectory reflected the visions that Yamanaka 
explicated originally in 2007 (cf., Hishiyama, 2010), and this document was produced after 
consultations with the key figures in the All-Japan research network for iPS cell research. It listed 
four research streams: two are mainly concerned about the quality of iPS cells, with the goals of 
improving the reprogramming technique and producing standardised cell lines; the other two focus 
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largely on applications, with the visions of the cells to be utilised in drug discovery and as 
regenerative medicine. However, it was soon revealed that the timelines suggested in this roadmap 
were almost impossible to meet – even from the viewpoints of the members of the research network. 
While stem cell scientists appeared to have achieved their legitimacy in this field owing to both 
political and public support, there was a growing concern among them that another failure to meet 
the expectation can easily overturn this situation. 
 
A major reason for this perceived impossibility was that collaboration necessary for attaining the 
goals set out in the roadmap proved difficult to implement. To promote the use of iPS cells for drug 
discovery, for example, the cells obtained from patients must be stocked at a cell bank and made 
available within the network. However, many researchers were reluctant to deposit their iPS cells 
until they publish several articles on them. Despite MEXT’s political attempt to set common goals 
for the iPS cell research network and to turn its projects into ‘big science’ working toward them, the 
researchers had little incentive, if any, to share their valuable resources because their personal as 
well as project’s merit was evaluated on the basis of peer-reviewed publications and possibly on the 
number of patents. Principal investigators, moreover, could not afford to let publication 
opportunities slip away, as they were responsible for the careers of their junior laboratory members. 
While this resource sharing problem did not totally abandon the cross-laboratory collaborations in 
the field, the researchers had to be careful choosing with whom they collaborate, necessarily 
involving a formal mode of contract, such as material transfer agreement, just as the conventional 
‘small’ life science research. Therefore, the laboratory-oriented style of stem cell science posed a 
major hurdle for developing ‘big-science’ collaboration that Yamanaka and MEXT envisioned in 
establishing their All-Japan network of iPS cell researchers. 
 
Bridging the Gap by Building a Highway 
 
 16 
Having publicised its expected trajectory in iPS cell research in 2009, MEXT became desperate to 
meet its targets. Some progress were made in the studies for improving the reprogramming 
technique and also for standardising iPS cells, as they were projects that Yamanaka and his new 
research centre CiRA played the central roles. Yamanaka’s public popularity, coupled with his 
medical background, also gave him access to some rare disease patients and allowed his group to 
advance drug discovery research using the cells obtained from them, though the scale of this work 
seem smaller than originally planned.6 A significant delay was observed particularly in the research 
stream for applications of iPS cells as regenerative medicine, and only a few areas, such as retinal 
regeneration, are expected to start their clinical research in the coming years. To reduce this delay, 
MEXT and the Ministry of Health, Labour and Welfare (MHLW) launched a new programme called 
the Regenerative Medicine Highway in 2011. 
 
This Highway programme was originally proposed by MEXT (2010) to overcome what it called the 
‘Death Valley’ in regenerative medicine, which prevents the transition from basic to applied 
research. In this programme, the two ministries harmonise their financial and other support for 
selected research projects and allow them to make seamless transitions from pre-clinical to clinical 
studies – a change needed to hasten the development of regenerative medicine. MEXT called for 
proposals in four distinctive categories: short-term projects aiming to start clinical research within 
three years; mid- or long-term projects targeting clinical research in five to seven years; projects set 
to provide technical support for research initiatives, including the Project for Realization of 
Regenerative Medicine; and projects studying and resolving the ethical challenges in regenerative 
medicine. Thus, the Highway programme is designed not only to provide policy support to 
independent research projects but also to establish common resources for their smooth running, and 
in the first selection procedure, a total of 10 projects were chosen for its funding. 
 
                                                 
6 Kyoto University established the Division for iPS Cell Application Development within its hospital in 2011 to be the 
contact point for patients willing to donate cells for iPS cell research. 
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Among these 10 projects, four were short-term and four were mid- and long-term. Overall, four of 
the 10 focus on clinical applications of iPS cells; yet retinal regeneration was the only such study 
selected for the short-term,7 reflecting delayed progress in iPS cell research. The three other short-
term projects aim to develop clinical applications of adult stem and somatic cells, instead of iPS 
cells, and all have a medical researcher at a university hospital as their principal investigator, 
indicating the two ministries’ intention to integrate the two clusters. Furthermore, a project aiming 
to develop clinical applications of hES cells was also selected for the mid- and long-term projects, 
alongside the three others focusing on iPS cells.8 As it was once commonly suggested that iPS cells 
would eliminate the need for hES cells, the inclusion of this research project within the Highway 
programme indicates a dramatic shift in the field of regenerative medicine research in Japan: 
investigators and funders alike are becoming more open to different styles of practices, so long as 
they are considered to be promising avenues for its advancement with some clinical relevance. 
 
Neither Okano nor Yamanaka is part of this Highway programme. Yet, a few projects aim to 
combine cell sheet engineering and iPS cells, and the medical researchers leading such projects, 
including Sawa, may bridge the gap that for a decade existed between the two clusters in this 
country. This application-oriented programme also allows commercial actors to participate, though 
they still perform supportive roles in the projects. While it is a collection of independent research 
projects, the collaboration between MEXT and the MHLW in the policy domain has provided some 
common grounds for regenerative medicine research and seemed to have created an accommodating 
environment for different styles of practices. 
 
                                                 
7 This research project is led by Masayo Takahashi at RIKEN CDB and the clinical studies are to be conducted at the 
neighbouring hospital, justifying its establishment about a decade ago in the Millennium Project and its visibility in 
regenerative medicine research since then. 
8 MEXT (2009) revised the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells in 2009 and 
clinical applications of pluripotent stem cells, including both hES cells and iPS cells, became permitted, but the main 
reason behind this decision was to allow those of iPS cells. 
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This shift, however, does not seem to bring about the convergence of the two clusters. In a MEXT 
committee meeting on stem cell science and regenerative medicine research in early 2012, a 
committee member commented that too much attention has been paid to iPS cells – particularly to 
their clinical applications – and that the abovementioned Highway programme to some extent 
relieved the burden on stem cell scientists, allowing them to retain their original interest in the 
biological mechanisms of stem cells. This comment indicates that the bridge between the two 
clusters is leading to their re-configuration, instead of their convergence: only the part of iPS cell 
research that is more compatible with the goal-oriented style of the other cluster is segregated from 
the mainstream stem cell science and can be merged with the cluster developed in university 
hospitals. Hence, this re-configuration would not only allow stem cell scientists to maintain their 
original style of pure science but also legitimise it by dissociating them from the policy emphasis on 
producing clinically useful knowledge. 
 
Again, this was not what Yamanaka envisioned when he proposed the All-Japan iPS cell research 
network back in late 2007, and his dissatisfaction with the state of collaboration in regenerative 
medicine research in Japan prompted him to recruit established researchers from other research 
groups within the network and enlarged his community at CiRA. To overcome the challenges that 
laboratory-based stem cell science posed for turning Japanese regenerative medicine research into 
‘big science’, he attempts to expand his research group and cover most aspects of iPS cell research 
at his centre. Establishing himself as a leader of iPS cell research may be an effective approach to 
facilitate research coordination in this field and direct it toward the goals that he envisioned and 
MEXT publicised, but, as suggested at the beginning of this chapter, there can be cost in ‘big 
science’ – at least, he becomes responsible for the careers of a large number of researchers, many of 
whom have to obtain a new post before the government funding ends. Whether he will succeed in 
both coordinating research activities and attaining the original goals remains uncertain. 
 
Discussion and Conclusion 
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In her study of research collaboration, Maienschein describes that ‘researchers collaborate for a 
variety of intellectual and social reasons: to get help, to combine expertise, to gain credibility, or to 
create a community’ (1993: 182). While each of these reasons may be applicable in any instance of 
research collaboration, the consistent rationale for collaborations in regenerative medicine research 
in Japan seems to have been the quest for legitimacy. To understand this, it is important to 
distinguish ‘legitimacy’ from ‘credibility’. In their ethnographic study, Latour and Woolgar (1979) 
argue that the circle of credit is central to research and that scientists invest their credit, obtained 
from various activities in research, in earning themselves the right to do more research – for 
instance, by obtaining research grants, buying the latest equipment and publishing journal articles. 
In collaboration, Maienschein (1993) also suggests, credibility may also be shared and expanded. 
Thus, ‘credibility’ in science works like one’s property, which can be obtained, possessed, invested 
and even shared. From this point of view, the idea of credibility resembles Bourdieu’s (1999) idea of 
‘scientific capital’, which functions just like other kinds of social capital, while specific to the ‘field’ 
of science: one accumulates by living as part of the community – receiving trainings, conducting 
research and presenting its result allow one to be recognised as part of the community from the 
peers. In contrast, ‘legitimacy’, for Bourdieu (1999), is about the power within the community, 
which must be achieved by accumulating scientific capital and possibly other social ones relevant to 
a field of science and ought to be exercised by influencing the peers. Achieving legitimacy is 
important because it is about the power not only to set the rules of its community but also to define 
the field. 
 
One’s scientific capitals can only be valuable so long as the community follows the same rule and 
recognise their value (see also Albert and Kleinman, 2011). In an interdisciplinary field, like 
regenerative medicine research, however, the rules are not clear – researchers may adopt different 
rules (cf., Panofsky, 2011). Furthermore, in this Japanese context, the value of scientific capitals 
seemed depreciated when stem cell science became part of the Millennium Genome Projects in 
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2000. The strong commitment of the government and its emphasis on ‘clinically useful’ knowledge 
forced stem cell scientists to adopt new rules of the game. However, with the structure of its 
community remained the same, they simply followed the original rules of ‘pure’ science, in which 
scientific credibility counts the most, and pursued their research on biological mechanisms of 
cellular development, differentiation and regeneration, mostly based on animal models. A few years 
later, they were criticised for not being ‘clinically relevant’. Despite their credibility accumulated 
during the Millennium policy initiative, they therefore failed to achieve legitimacy and set their own 
rules of the game. MEXT then launched the Project for Realization of Regenerative Medicine in 
2003 urging them to re-structure the community, again insisting the importance of clinical 
usefulness. Yet again, they struggled to team up with medical doctors, who do not value their 
scientific capitals much, resulting in upholding of their own cluster. 
 
In contrast to such struggle of stem cell scientists, biomedical engineers experienced little 
difficulties working with active surgeons. They had been developing novel techniques on less 
complex adult somatic cells, and some of the techniques were quite ready for clinical studies. 
Surgeons, interested in treating patients primarily, were willing to collaborate with them and to test 
such techniques. This hospital-based collaboration was only possible where patients agree to 
participate in the studies, and hence patient participation served as the valuable social capital for 
them, indicating relevance of their research as regenerative medicine. However, they were not 
successful enough (or maybe they were not fast enough) to achieve legitimacy and set the rules in 
the field: their collaborations remained confined to hospitals spaces, where the discretionary right of 
medical doctors is reserved. 
 
This situation changed dramatically in 2007 when Yamanaka announced the creation of human iPS 
cells. The development of the reprogramming technique in 2006 allowed him to accumulate 
credibility within the community of stem cell science, and then by demonstrating its applicability to 
human cells he successfully translated this credibility into social capital relevant to the field of 
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regenerative medicine research. Unlike hospital-based collaborations, he has not been able to 
acquire much social capital of patient participation through iPS cell research, but instead by 
publicising his visions of using the new cells for drug discovery and as regenerative medicine he 
managed to frame the general public as a group of potential patients, who would benefit from 
advances in iPS cell research, and turn their support as the evidence of its clinical relevance. As 
discussed in the sociology of expectations (e.g. Brown et al., 2000; Brown and Michael, 2003), he 
mobilised resources in the present by presenting a scenario of the future – the enthusiastic support 
from healthy members of the public might not have been recognised as the valuable ‘capital’, unless 
they recognised usefulness of his research and accepted that it was clinical rather than basic (cf., 
Shineha et al., 2010). 
 
MEXT attempted to affirm Yamanaka’s legitimacy and make his visions as the basis of the new 
rules in this field by establishing the All-Japan network for iPS cell research. Yet, its attempt failed: 
the tension arisen within the network left the visions ‘unrealistic’ and hence its future value left 
unverified. The Ministry reacted to this by launching another programme with the MHLW. Their 
goal-oriented Highway programme, as discussed in the studies of innovation policy (e.g. Gibbons et 
al., 1994), enrolled diverse actors, including not only the members of the stem cell science cluster 
but also those of the other cluster, who have accumulated capitals of patient participation over the 
years. To some extent, MEXT managed to bridge the gap between the two clusters. Yet, some stem 
cell scientists considered this programme as a long-awaited opportunity to re-establish their own 
field where credibility is intertwined closely with legitimacy, that is, the ideal world of ‘pure’ 
science (cf., Bourdieu, 1999). Yamanaka, rather than participating in this programme and becoming 
part of the re-configured cluster, upholds his original visions of iPS cell research and tries to protect 
his legitimacy by expanding his own research centre. 
 
According to Gieryn (1983), scientists often demonstrate their legitimacy by drawing the boundary 
against ‘non-science’ and by presenting themselves as the producers of ‘valuable’ knowledge. In 
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other words, they maintain the value of credibility in science by purifying the community (Bourdieu, 
1999). However, as this study of regenerative medicine research in Japan shows, the value of life 
science research is increasingly tied to its ‘clinical relevance’, and patient participation is becoming 
a major resource for one’s legitimacy. The boundaries of the clusters in this field therefore have 
been drawn and re-drawn to integrate the figures of patients as its main capitals. The integration of 
patient figures and hence the demonstration of clinical relevance, however, are more compatible 
with some styles of practice than others. Thus, biomedical engineers and surgeons have been able to 
maintain their style at the same time as they accumulate their capitals, while stem cell scientists 
insisting on their own style struggled to achieve legitimacy. Despite their dramatic revival since late 
2007, some stem cell scientists have been keen to re-draw a boundary again between ‘basic’ and 
‘applied’ research so as to go back to where they started in 2000. 
 
This study also demonstrates that a field of science is being shaped not only by the researchers’ 
attempt to draw its boundaries but also by the government’s attempts to justify their policy 
decisions. This government’s influence to some extent confirms mutual reliance between science 
and policy (e.g. Jasanoff, 1990; Shackley and Wynne, 1995), but it seems important for the 
government to commit the right kind of a cluster, or otherwise it needs to make the one it already 
committed right because researchers tend to form different clusters. This rightness again has to be 
defined by the rules of the game in the field. The Japanese government’s commitment with stem cell 
science in early 2000s could have proved successful if this field was simply of ‘pure’ science: the 
researchers made significant advancement and obtained scientific credibility since the beginning of 
the new millennium. However, the emphasised importance of ‘clinical relevance’ posed it a 
significant challenge. Yamanaka’s creation of human iPS cells provided the government an 
opportunity to re-configure the cluster and justify its commitment after its unsuccessful attempts of 
the Millennium Genome Projects and the Project for Realization of Regenerative Medicine. 
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However, the initiatives on iPS cell research also turned out to be not as successful as expected 
because of the persistent tension within the established research network. In his study of molecular 
biologists, Hackett (2005) argues that such tension is critical part of ‘cooperative competition’ in life 
science. Each research group in the network wanted to make breakthroughs and obtain credibility in 
the field, but staying in the cluster was a strategic decision for it to have access to newly created iPS 
cells and enjoy the substantial research support. Before it discloses its findings and shares the data 
and materials produced in its research, however, the group needs to make sure that it takes full 
advantage of them and is better positioned in setting the rules in the field than its cooperating 
competitors. While Chompalov and his colleagues argue that those ‘who produces an innovative 
[style of practice] could well be making the collaboration’s task more difficult’ (2002: 760), 
therefore, researchers in an emerging field like this have strong motivation to develop an innovative 
style and set the rules for the field. This kind of tension might have been resolved, just like the 
healthy tension within a single laboratory, if the network had a clear ‘leader’ to take control over 
activities of its members. 
 
This policy failure provided the background for Yamanaka’s gradual shift away from the 
‘participatory’ national network to the formal hierarchy at his research centre CiRA. As a director of 
the centre, Yamanaka is able to set rules and coordinate the work of its members toward the shared 
goals, reflecting his own visions. This can also be seen as a case of ‘mezzo’ science emerged from 
the bigger one (cf., Vermeulen et al., 2010). This kind of intra-organisational collaboration can be 
advantageous in several ways: its formal structure can introduce the division of labour among the 
researchers, which ‘ensures a more effective use of their talents’ (Katz and Martin, 1997: 14); their 
physical proximity can also allow them to share their skills and tacit knowledge, which may not be 
conveyed through published journal articles (Katz and Martin, 1997), and finally sharing of limited 
time and space of research facilities, just as the case of an accelerator laboratories (Champalov et al., 
2002), would prompt them to have more communications. As a director of the centre, Yamanaka is 
also able to adopt a different set of criteria for assessing the contribution of each member from that 
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agreed within the cluster of regenerative medicine research. Just as MEXT and the MHLW designed 
in their programme, building technical and ethical resources available for its member researchers is 
considered to be critical for advancing this field further and Yamanaka seems keen to develop such 
non-scientific expertise within his research centre too. 
 
Coordinating research activities of researchers can be a daunting task, but as Hackett (2005) suggest, 
a leader does not have to be good at everything but only needs to be good at articulation work, 
allowing its members to be part of the project with confidence in their future. The coming years will 
be a testament to coordination skills of Yamanaka, who have already shown his scientific 
excellence. 
 
Thus, the 2012 JSRM public lecture was not only a showcase of the state-of-the-art research in this 
field but also that of the research clusters of which it consisted. Yamanaka engaged Takuro Tatsumi 
representing healthy members of the public, explained the values of his iPS cell research to the 
audiences and left the room. Having achieved the heroic status among the public, he had other 
businesses to do to maintain his legitimacy and to keep his research going. Left in the room were the 
two other academic speakers, Okano and Sawa. The biomedical engineer talked about his research 
accomplishments, which might be of interest to both academic researchers and commercial actors 
sitting in the room, who could be his future collaborators; their technical complication, however, 
discouraged most public audience to engage with his research directly. In contrast, the surgeon 
managed not only to demonstrate his past engagement with actual patients but also to build the link 
between the biomedical engineer and the public audience, serving as a ‘host’ for both. All the 
speakers tried to demonstrate their legitimacy in this underdetermined field of regenerative medicine 
research, but they did so in different ways reflecting their views on what is (and ought to be) valued 
in the field. Needless to say, no other stem cell scientist than Yamanaka spoke in this lecture, as he 
would have insisted that legitimacy could only be achieved by convincing fellow scientists and 
earning credibility from them, rather than engaging with the public audience. 
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